FindTrial
Sign In

To study the immunohistochemical expression of sorcin in gall bladder cancer

Immunosuppression of sorcin and its association with clinico-pathological parameters in gall bladder adenocarcinoma - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070393
Enrollment
60
Registered
2024-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K828- Other specified diseases of gallbladder

Interventions

Control Intervention1: NIL: NIL

Sponsors

G B Pant institute of post graduate medical education and research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Adult patients undergoing cholecystectomy in view of suspected gall bladder lesions during the study period 2)Patients diagnosed as gall bladder adenocarcinoma on cholecystectomy specimens.

Exclusion criteria

Exclusion criteria: 1)Cases diagnosed as histological subtype other than adenocarcinoma 2)Post chemotherapy cases

Design outcomes

Primary

MeasureTime frame
Prevalence of Sorcin immunoexpression in gall bladder adenocarcinomaTimepoint: Baseline—

Secondary

MeasureTime frame
Association of Sorcin expression with clinico-pathological parametersTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Surbhi Goyal

G B Pant institute of post graduate medical education and research

dr.surbhi4you@gmail.com9873896416

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026